Literature DB >> 8825043

Diagnosis of malignant hyperthermia: a comparison of the in vitro contracture test with the molecular genetic diagnosis in a large pedigree.

J M Healy1, K A Quane, K E Keating, M Lehane, J J Heffron, T V McCarthy.   

Abstract

Malignant hyperthermia (MH) is an inherited skeletal muscle disorder and is one of the major causes of death resulting from anaesthesia. MH is currently diagnosed by the in vitro contracture test performed on a muscle biopsy. Genetic linkage analysis on an Irish MH pedigree showed that when the thresholds for the standardised European protocol for MHS diagnosis was applied, linkage between the MHS phenotype and the RYR1 locus was excluded. When we raised the threshold values for assignment of MHS status and assumed MHN diagnosis in subjects where this threshold was not attained, tight linkage between MHS and RYR1 markers was observed, suggesting that MHS is linked to the RYR1 locus in this pedigree. Confirmation of these results was borne out by the fact that all of the MHS patients in the pedigree exceeding the raised threshold carried the known MHS Gly341Arg RYR1 mutation. The results obtained could be explained (1) by false positive diagnosis of MHS in the recombinant subjects, (2) by the presence of a mutation in a predisposing gene other than RYR1, or (3) by the presence of mild subclinical myopathies. The implications of these results for heterogeneity studies is discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8825043      PMCID: PMC1051806          DOI: 10.1136/jmg.33.1.18

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  26 in total

1.  Evaluation of 119 anaesthetics received after investigation for susceptibility to malignant hyperthermia.

Authors:  H Ording; A M Hedengran; L T Skovgaard
Journal:  Acta Anaesthesiol Scand       Date:  1991-11       Impact factor: 2.105

2.  Dinucleotide repeat polymorphism at the RYR1 locus (19q13.1).

Authors:  F J Couch; K Hogan; T V McCarthy; R G Gregg
Journal:  Nucleic Acids Res       Date:  1991-09-25       Impact factor: 16.971

3.  Dinucleotide repeat polymorphism at the D19S75 locus.

Authors:  J L Weber; C Kappel; P E May; A E Kwitek
Journal:  Nucleic Acids Res       Date:  1990-08-11       Impact factor: 16.971

Review 4.  Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group.

Authors:  M G Larach
Journal:  Anesth Analg       Date:  1989-10       Impact factor: 5.108

5.  Central-core disease and malignant hyperpyrexia.

Authors:  M A Denborough; X Dennett; R M Anderson
Journal:  Br Med J       Date:  1973-02-03

6.  A comparison of the caffeine halothane muscle contracture test with the molecular genetic diagnosis of malignant hyperthermia.

Authors:  A E MacKenzie; G Allen; D Lahey; M L Crossan; K Nolan; G Mettler; R G Worton; D H MacLennan; R Korneluk
Journal:  Anesthesiology       Date:  1991-07       Impact factor: 7.892

7.  A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia.

Authors:  E F Gillard; K Otsu; J Fujii; V K Khanna; S de Leon; J Derdemezi; B A Britt; C L Duff; R G Worton; D H MacLennan
Journal:  Genomics       Date:  1991-11       Impact factor: 5.736

8.  Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility.

Authors:  G C Allen; H Rosenberg; J E Fletcher
Journal:  Anesthesiology       Date:  1990-04       Impact factor: 7.892

9.  Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1.

Authors:  R Sudbrak; V Procaccio; M Klausnitzer; J L Curran; K Monsieurs; C van Broeckhoven; R Ellis; L Heyetens; E J Hartung; G Kozak-Ribbens
Journal:  Am J Hum Genet       Date:  1995-03       Impact factor: 11.025

10.  Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia.

Authors:  D H MacLennan; C Duff; F Zorzato; J Fujii; M Phillips; R G Korneluk; W Frodis; B A Britt; R G Worton
Journal:  Nature       Date:  1990-02-08       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.